SG10202007639SA - Compositions and methods related to multimodal therapeutic cell systems for immune indications - Google Patents
Compositions and methods related to multimodal therapeutic cell systems for immune indicationsInfo
- Publication number
- SG10202007639SA SG10202007639SA SG10202007639SA SG10202007639SA SG10202007639SA SG 10202007639S A SG10202007639S A SG 10202007639SA SG 10202007639S A SG10202007639S A SG 10202007639SA SG 10202007639S A SG10202007639S A SG 10202007639SA SG 10202007639S A SG10202007639S A SG 10202007639SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- cell systems
- methods related
- therapeutic cell
- multimodal therapeutic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277130P | 2016-01-11 | 2016-01-11 | |
| US201662359448P | 2016-07-07 | 2016-07-07 | |
| US201662370915P | 2016-08-04 | 2016-08-04 | |
| US201662420973P | 2016-11-11 | 2016-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202007639SA true SG10202007639SA (en) | 2020-09-29 |
Family
ID=57907000
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202007639SA SG10202007639SA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| SG11201805253SA SG11201805253SA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| SG10201913837TA SG10201913837TA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| SG11201805442XA SG11201805442XA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805253SA SG11201805253SA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| SG10201913837TA SG10201913837TA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| SG11201805442XA SG11201805442XA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US10456421B2 (hu) |
| EP (3) | EP4019026A1 (hu) |
| JP (5) | JP7093302B2 (hu) |
| KR (2) | KR20180095098A (hu) |
| CN (3) | CN108697733A (hu) |
| AU (2) | AU2017207738A1 (hu) |
| BR (2) | BR112018013853A2 (hu) |
| CA (2) | CA3010510A1 (hu) |
| DK (1) | DK3402491T3 (hu) |
| ES (1) | ES2907695T3 (hu) |
| HK (1) | HK1259079A1 (hu) |
| HR (1) | HRP20220147T1 (hu) |
| HU (1) | HUE057660T2 (hu) |
| IL (2) | IL260010A (hu) |
| LT (1) | LT3402491T (hu) |
| MX (2) | MX2018008515A (hu) |
| PL (1) | PL3402491T3 (hu) |
| PT (1) | PT3402491T (hu) |
| RS (1) | RS62939B1 (hu) |
| SG (4) | SG10202007639SA (hu) |
| SI (1) | SI3402491T1 (hu) |
| WO (2) | WO2017123644A1 (hu) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2768942T (lt) | 2011-10-17 | 2020-04-10 | Massachusetts Institute Of Technology | Pristatymas į ląstelės vidų |
| KR102304167B1 (ko) | 2013-08-16 | 2021-09-24 | 메사추세츠 인스티튜트 오브 테크놀로지 | 세포로의 선택적 물질 전달 |
| JP6702866B2 (ja) | 2013-11-18 | 2020-06-03 | ルビウス セラピューティクス， インコーポレイテッド | 合成膜−レシーバー複合体 |
| JP6735233B2 (ja) | 2014-04-01 | 2020-08-05 | ルビウス セラピューティクス， インコーポレイテッド | 免疫調節方法及び組成物 |
| RU2020139190A (ru) | 2014-10-31 | 2021-01-26 | Массачусетс Инститьют Оф Текнолоджи | Доставка биомолекул в клетки иммунной системы |
| JP6846345B2 (ja) | 2014-11-14 | 2021-03-24 | マサチューセッツ インスティテュート オブ テクノロジー | 破壊及び場による細胞への化合物及び組成物の送達 |
| EP3245294A4 (en) | 2015-01-12 | 2018-05-30 | Massachusetts Institute of Technology | Gene editing through microfluidic delivery |
| JP6925984B2 (ja) | 2015-07-09 | 2021-08-25 | マサチューセッツ インスティテュート オブ テクノロジー | 無核細胞への物質の送達 |
| WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| SI3402491T1 (sl) | 2016-01-11 | 2022-05-31 | Rubius Therapeutics, Inc. | Sestavki in postopki v zvezi z multimodalnimi terapevtskimi celičnimi sistemi za indikacije raka |
| AU2018221227A1 (en) | 2017-02-17 | 2019-08-15 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| GB2597623A (en) | 2017-08-07 | 2022-02-02 | Univ California | Platform for generating safe cell therapeutics |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| KR20200064083A (ko) * | 2017-09-07 | 2020-06-05 | 큐 바이오파마, 인크. | 항원-제시 폴리펩티드 및 이의 사용 방법 |
| WO2019113512A1 (en) * | 2017-12-07 | 2019-06-13 | Flagship Pioneering Innovations V, Inc. | Cytobiologics and therapeutic uses thereof |
| EP3727434A1 (en) * | 2017-12-23 | 2020-10-28 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells and methods of use |
| CA3093387A1 (en) * | 2018-03-08 | 2019-09-12 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
| US20210208163A1 (en) * | 2018-05-24 | 2021-07-08 | Rush University Medical Center | ICOSL for use as a Renal Therapeutic |
| US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
| EP3911745A1 (en) | 2019-01-18 | 2021-11-24 | Flagship Pioneering, Inc. | Trem compositions and uses thereof |
| JP2022521738A (ja) * | 2019-02-20 | 2022-04-12 | ルビウス セラピューティクス， インコーポレイテッド | 負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法 |
| AU2020233404A1 (en) | 2019-03-04 | 2021-09-16 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides and pharmaceutical compositions thereof |
| JP2022526492A (ja) * | 2019-03-18 | 2022-05-25 | バイオ－ラッド エービーディー セロテック ゲーエムベーハー | 複数のｆｃアイソタイプ及びサブクラスに結合した抗原結合フラグメント |
| CA3131319A1 (en) | 2019-03-25 | 2020-10-01 | Avak Kahvejian | Compositions comprising modified circular polyribonucleotides and uses thereof |
| WO2020223657A1 (en) * | 2019-05-02 | 2020-11-05 | Predictive Technology Group, Inc. | Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk |
| CN114269921A (zh) | 2019-05-31 | 2022-04-01 | 旗舰创业股份有限公司 | TREM组合物用以调节tRNA池的用途 |
| JP2022537154A (ja) | 2019-06-14 | 2022-08-24 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 細胞治療のための環状ｒｎａ |
| EP3986469A1 (en) | 2019-06-19 | 2022-04-27 | Flagship Pioneering Innovations VI, LLC | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
| CN112195154B (zh) * | 2019-07-08 | 2024-03-29 | 江苏汇智生物科技有限公司 | 一种基因改造表达改造型pla2r受体的细胞及其应用 |
| BR112022004073A2 (pt) | 2019-09-05 | 2022-05-31 | Hemanext Inc | Métodos para a preservação de glóbulos vermelhos reagentes usando monóxido de carbono |
| WO2021073613A1 (en) * | 2019-10-18 | 2021-04-22 | Westlake Therapeutics (Hangzhou) Co. Limited | Engineered red blood cells presenting specific cancer neoantigen with artificial mhc |
| EP4055169A1 (en) | 2019-11-04 | 2022-09-14 | Flagship Pioneering, Inc. | Methods of modifying a nucleic acid sequence |
| CN115003810A (zh) | 2019-11-04 | 2022-09-02 | 旗舰创业股份有限公司 | 用于con-稀有密码子的trem组合物及相关用途 |
| TW202142239A (zh) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | 包含環狀多核糖核苷酸之組合物之遞送 |
| EP4096715A1 (en) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Compositions comprising linear polyribonucleotides for protein modulation and uses thereof |
| US20230181620A1 (en) | 2020-01-29 | 2023-06-15 | Flagship Pioneering Innovations Vi, Llc | Compositions for translation and methods of use thereof |
| WO2021158991A1 (en) * | 2020-02-07 | 2021-08-12 | The Regents Of The University Of California | Methods and use for bioengineering enucleated cells |
| IL298363A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| IL298362A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Corona virus antigen compositions and their uses |
| US20230203192A1 (en) | 2020-05-20 | 2023-06-29 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
| CA3180101A1 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods relating thereto |
| EP4158032A2 (en) | 2020-05-29 | 2023-04-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and methods relating thereto |
| WO2021262799A1 (en) | 2020-06-23 | 2021-12-30 | Flagship Pioneering, Inc. | Anti-viral compounds and methods of using same |
| TW202218669A (zh) | 2020-09-03 | 2022-05-16 | 美商旗艦先鋒創新有限責任公司 | 免疫原性組成物及其用途 |
| US20240175020A1 (en) | 2020-12-23 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| WO2022150569A1 (en) | 2021-01-08 | 2022-07-14 | Rubius Therapeutics, Inc. | METHODS OF INCREASING NKp30-POSITIVE LYMPHOCYTES IN A SUBJECT AND USES THEREOF |
| KR20230160823A (ko) * | 2021-02-26 | 2023-11-24 | 사이토누스 테라퓨틱스, 인크. | 치료 전달을 위한 조성물 및 방법 |
| TW202304482A (zh) | 2021-03-14 | 2023-02-01 | 美商盧比亞斯治療公司 | 於個體中增加nkg2d陽性淋巴球之方法及其用途 |
| WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4377457A1 (en) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and uses thereof |
| CA3232635A1 (en) | 2021-09-17 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
| EP4415848A1 (en) * | 2021-10-12 | 2024-08-21 | Cytonus Therapeutics, Inc. | Systems and methods for manufacturing of therapeutic cells |
| AU2022370530A1 (en) | 2021-10-18 | 2024-05-02 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| AU2022397292A1 (en) | 2021-11-24 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
| EP4436984A1 (en) | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
| CN118555966A (zh) | 2021-11-24 | 2024-08-27 | 旗舰创业创新六公司 | 免疫原性组合物及其用途 |
| TW202340461A (zh) | 2021-12-22 | 2023-10-16 | 美商旗艦先鋒創新有限責任公司 | 用於純化多核糖核苷酸之組成物和方法 |
| WO2023122789A1 (en) | 2021-12-23 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| WO2023220729A2 (en) | 2022-05-13 | 2023-11-16 | Flagship Pioneering Innovations Vii, Llc | Double stranded dna compositions and related methods |
| WO2023230570A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating genetic drivers |
| WO2023230566A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating cytokines |
| WO2023230549A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of tumor suppressors and oncogenes |
| WO2023230573A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of immune responses |
| WO2023230578A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating circulating factors |
| WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| WO2024059740A1 (en) * | 2022-09-14 | 2024-03-21 | Synthego Corporation | Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| WO2024102799A1 (en) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
| WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
| US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| US20240293582A1 (en) | 2023-02-17 | 2024-09-05 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified cytosine |
| WO2024173828A1 (en) | 2023-02-17 | 2024-08-22 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified uracil |
| WO2024192420A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
| WO2024192422A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026290A1 (en) * | 1993-05-07 | 1994-11-24 | Immunex Corporation | Cytokine designated 4-1bb ligand and human receptor that binds thereto |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US20020151004A1 (en) * | 2000-07-24 | 2002-10-17 | Roger Craig | Delivery vehicles and methods for using the same |
| AU2002213251B2 (en) | 2000-10-16 | 2007-06-14 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| WO2004087876A2 (en) * | 2003-03-25 | 2004-10-14 | Valeocyte Therapies Llc | Use of red blood cells to facilitate cell activation |
| DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| FR2884717B1 (fr) | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
| PL3263581T3 (pl) | 2005-05-17 | 2021-05-04 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| WO2007030708A2 (en) | 2005-09-08 | 2007-03-15 | Adnexus Therapeutics, Inc. | Antimicrobial adzymes and uses thereof |
| US7462485B2 (en) | 2005-10-07 | 2008-12-09 | Glaser Lawrence F | Modified erythrocytes and uses thereof |
| FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| FR2925339B1 (fr) | 2007-12-24 | 2010-03-05 | Erytech Pharma | Medicament pour le traitement du cancer du pancreas |
| ES2405258T3 (es) | 2008-02-13 | 2013-05-30 | Erytech Pharma | Formulación y procedimiento para la prevención y el tratamiento de la manifestación esquelética de la enfermedad de Gaucher |
| FR2928270B1 (fr) | 2008-03-10 | 2011-01-21 | Erytech Pharma | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
| US8211656B2 (en) * | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
| FR2938332B1 (fr) | 2008-11-07 | 2011-11-25 | Erytech Pharma | Test predictif de la neutralisation de l'activite asparaginase |
| FR2944106B1 (fr) | 2009-04-03 | 2012-09-28 | Erytech Pharma | Methode de dosage de l'inositol hexaphosphate (ihp). |
| EP2493487B1 (en) | 2009-10-27 | 2016-08-24 | Erytech Pharma | Composition to induce specific immune tolerance |
| JP6017422B2 (ja) * | 2010-08-10 | 2016-11-02 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） | 赤血球結合療法 |
| EP4052717A1 (en) | 2012-03-13 | 2022-09-07 | Celularity Inc. | Modified erythrocyte precursor cells and uses thereof |
| EP2827878A1 (en) | 2012-03-21 | 2015-01-28 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (aml) |
| CN103224957B (zh) | 2013-04-16 | 2017-08-04 | 福建三一造血技术有限公司 | 体外诱导生成含L‑ASPase II的红细胞药物的方法 |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| WO2014183071A2 (en) | 2013-05-10 | 2014-11-13 | Whitehead Institute For Biomedical Research | In vitro production of red blood cells with sortaggable proteins |
| WO2014183066A2 (en) | 2013-05-10 | 2014-11-13 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| EP2813234A1 (en) | 2013-06-11 | 2014-12-17 | Erytech Pharma | Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof |
| JP6702866B2 (ja) | 2013-11-18 | 2020-06-03 | ルビウス セラピューティクス， インコーポレイテッド | 合成膜−レシーバー複合体 |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| JP6735233B2 (ja) | 2014-04-01 | 2020-08-05 | ルビウス セラピューティクス， インコーポレイテッド | 免疫調節方法及び組成物 |
| US20180135012A1 (en) | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| EP3187190A1 (en) | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| SI3402491T1 (sl) | 2016-01-11 | 2022-05-31 | Rubius Therapeutics, Inc. | Sestavki in postopki v zvezi z multimodalnimi terapevtskimi celičnimi sistemi za indikacije raka |
| JP2019520829A (ja) | 2016-07-07 | 2019-07-25 | ルビウス セラピューティクス， インコーポレイテッド | 外来性ｒｎａを発現する治療的細胞系に関連する組成物及び方法 |
| BR112019011138A2 (pt) * | 2016-12-02 | 2019-10-01 | Rubius Therapeutics Inc | composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos |
| AU2018221227A1 (en) | 2017-02-17 | 2019-08-15 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| US20190062788A1 (en) | 2017-08-22 | 2019-02-28 | Rubius Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| US20190160102A1 (en) | 2017-11-03 | 2019-05-30 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
| WO2019133881A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for enginerering erythroid cells |
-
2017
- 2017-01-11 SI SI201731074T patent/SI3402491T1/sl unknown
- 2017-01-11 JP JP2018535844A patent/JP7093302B2/ja active Active
- 2017-01-11 RS RS20220172A patent/RS62939B1/sr unknown
- 2017-01-11 DK DK17701776.1T patent/DK3402491T3/da active
- 2017-01-11 SG SG10202007639SA patent/SG10202007639SA/en unknown
- 2017-01-11 SG SG11201805253SA patent/SG11201805253SA/en unknown
- 2017-01-11 SG SG10201913837TA patent/SG10201913837TA/en unknown
- 2017-01-11 MX MX2018008515A patent/MX2018008515A/es unknown
- 2017-01-11 AU AU2017207738A patent/AU2017207738A1/en not_active Abandoned
- 2017-01-11 EP EP21216483.4A patent/EP4019026A1/en not_active Withdrawn
- 2017-01-11 CA CA3010510A patent/CA3010510A1/en active Pending
- 2017-01-11 LT LTEPPCT/US2017/013035T patent/LT3402491T/lt unknown
- 2017-01-11 KR KR1020187022922A patent/KR20180095098A/ko unknown
- 2017-01-11 ES ES17701776T patent/ES2907695T3/es active Active
- 2017-01-11 AU AU2017207736A patent/AU2017207736A1/en not_active Abandoned
- 2017-01-11 BR BR112018013853A patent/BR112018013853A2/pt not_active Application Discontinuation
- 2017-01-11 HR HRP20220147TT patent/HRP20220147T1/hr unknown
- 2017-01-11 JP JP2018535851A patent/JP2019501655A/ja active Pending
- 2017-01-11 PL PL17701776T patent/PL3402491T3/pl unknown
- 2017-01-11 EP EP17701776.1A patent/EP3402491B1/en active Active
- 2017-01-11 WO PCT/US2017/013033 patent/WO2017123644A1/en active Application Filing
- 2017-01-11 KR KR1020187022906A patent/KR20180095713A/ko unknown
- 2017-01-11 SG SG11201805442XA patent/SG11201805442XA/en unknown
- 2017-01-11 HU HUE17701776A patent/HUE057660T2/hu unknown
- 2017-01-11 PT PT177017761T patent/PT3402491T/pt unknown
- 2017-01-11 CN CN201780006113.4A patent/CN108697733A/zh active Pending
- 2017-01-11 EP EP17703498.0A patent/EP3402492B1/en active Active
- 2017-01-11 WO PCT/US2017/013035 patent/WO2017123646A1/en active Application Filing
- 2017-01-11 CA CA3009063A patent/CA3009063A1/en active Pending
- 2017-01-11 CN CN201780006086.0A patent/CN108778298A/zh active Pending
- 2017-01-11 MX MX2018008514A patent/MX2018008514A/es unknown
- 2017-01-11 BR BR112018013728A patent/BR112018013728A2/pt not_active Application Discontinuation
- 2017-01-11 CN CN202211081626.0A patent/CN115969987A/zh not_active Withdrawn
- 2017-09-26 US US15/716,141 patent/US10456421B2/en not_active Expired - Fee Related
-
2018
- 2018-02-26 US US15/905,445 patent/US20180187155A1/en not_active Abandoned
- 2018-02-27 US US15/906,873 patent/US10568910B2/en not_active Expired - Fee Related
- 2018-06-13 IL IL260010A patent/IL260010A/en unknown
- 2018-06-13 IL IL259991A patent/IL259991A/en unknown
- 2018-12-03 US US16/207,568 patent/US10716811B2/en not_active Expired - Fee Related
-
2019
- 2019-01-29 HK HK19101579.6A patent/HK1259079A1/zh unknown
- 2019-09-18 US US16/574,830 patent/US10517897B1/en not_active Expired - Fee Related
-
2020
- 2020-01-08 US US16/737,661 patent/US20200129556A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021031998A patent/JP2021078519A/ja active Pending
- 2021-05-13 JP JP2021081727A patent/JP2021112216A/ja active Pending
- 2021-11-17 US US17/528,422 patent/US20220072048A1/en active Pending
-
2022
- 2022-09-16 JP JP2022148073A patent/JP2022171843A/ja not_active Withdrawn
-
2023
- 2023-01-25 US US18/159,229 patent/US20230293588A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1259079A1 (zh) | 與免疫適應症的多模式治療性細胞體系有關的組合物和方法 | |
| HK1258041A1 (zh) | 免疫細胞組合物和使用方法 | |
| IL266940A (en) | Preparations and methods related to cell systems for infiltrating solid tumors | |
| HK1244826A1 (zh) | 用於過繼細胞治療的方法和組合物 | |
| IL277593A (en) | Preparations and methods for the induction of lifelong T cells for 8 CD | |
| HK1243333A1 (zh) | 用於修飾的t細胞的方法和組合物 | |
| HK1244841A1 (zh) | 用於選擇性消除所關注細胞的方法和組合物 | |
| ZA201903333B (en) | Photovoltaic system and associated use | |
| EP3215495A4 (en) | Skincare formulations and regimens | |
| IL250582B (en) | Compositions and methods for early screening of medical components | |
| HK1252778A1 (zh) | 細胞擴增方法和治療組合物 | |
| IL259202A (en) | Modified immune cells and their use | |
| HK1256033A1 (zh) | 用於刺激免疫系統的肽 | |
| ZA201706794B (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| EP3439688A4 (en) | COMPOSITIONS AND METHODS IN CONNECTION WITH POLYCYTOTOXIC T CELLS | |
| EP3097420A4 (en) | Methods and compositions for immune dis-inhibition | |
| PL3187258T3 (pl) | Ulepszenia w reaktorach lub z nimi związane | |
| SG11202000811RA (en) | Methods for activating immune cells | |
| PL3277658T3 (pl) | Sposób i system do syntezy biodiesla | |
| EP3178223A4 (en) | Systems and methods to achieve interactive special effects | |
| HK1198238A2 (en) | Solar charging system and apparatus | |
| SG11201702105QA (en) | Methods and systems for camptothecin analog synthesis | |
| GB201419559D0 (en) | Therapeutic compositions and methods | |
| AU2014901390A0 (en) | Immune cell markers and uses thereof | |
| AU2014901389A0 (en) | Immune cell markers and uses thereof |